Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
This is an observational, prospective, open-label, single-arm, multicenter, real-life study
 designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen
 (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in
 participants with HCV GT1.
Inclusion Criteria:

 -  Treatment-naïve participants

 -  Mono-infected participants with chronic HCV GT1

 -  Non-cirrhotic participants

 -  Participants with debilitating fatigue (Fatigue Severity Scale [FSS] greater than or
 equal to 4)

 Exclusion Criteria:

 -  Participants with sources of fatigue other than HCV (especially, severe depression,
 cancer and hormonal disorders causing clinically significant fatigue)

 -  Participants with conditions that do not allow to adhere to protocol and use of the
 device at investigator's discretion

 -  Participants who are wheelchair dependent